Recent evidence demonstrates ANL’s capacity to reshape the tumor immune microenvironment and enhance anti-PD-1 efficacy through modulation of the VEGFR2/AKT/HIF-1α axis and TFRC-CXCL14 signaling (Song et al., 2024). The gene discussed is AKT1; the disease is neoplasm.